Expand REPL Menu
REPL MENU

REPL Latest Press Releases

-- May 29, 2026 --

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA Globe Newswire 8:00 AM

-- May 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 6:07 PM

-- May 17, 2026 --

REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 9:49 PM

-- May 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 8:15 PM

-- May 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 5:24 PM

-- April 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL PRNewswire 9:42 PM

-- April 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 5:25 PM

-- April 27, 2026 --

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 8:00 AM

-- April 21, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL Globe Newswire 4:42 PM

-- April 13, 2026 --

Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 7:45 AM

-- April 10, 2026 --

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma Globe Newswire 5:13 PM
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma Globe Newswire 5:13 PM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM
Replimune to Present at Two Upcoming Investor Conferences Globe Newswire 8:00 AM

-- February 5, 2026 --

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL), Sable Offshore Corp. (SOC), Sarepta Therapeutics, Inc. (SRPT), and Semler Scientific, Inc. (SMLR) Globe Newswire 10:47 AM

-- February 3, 2026 --

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- January 20, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE) Globe Newswire 9:31 AM
Market Data Delayed 15 Minutes